NEXI-001
Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: an Adoptive Cellular Therapy for Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from Matched HLA Donors
What's the purpose of the trial?
Not yet accepting
For Healthcare Professionals Only
This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Decitabine is a type of chemotherapy called a hypomethylating agent that interferes with the growth and spread of cancer cells in the body.
- Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
- NEXI-001 is an experimental CD8+ T cell product being tested in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.